GoldBamboo.com - Knowledge is strong medicine
  

Assessment of oral acyclovir in neonates with HSV involving the CNS - Article


  Not Signed In - Sign In / Register






Metoclopramide Oral Solution

Reglan



Clinical Trial: Assessment of oral acyclovir in neonates with HSV involving the CNS

This study is currently recruiting patients.

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this study is to test whether long-term treatment (6 months) with oral acyclovir improves the outcome for infants with HSV infection of the brain or spinal cord (central nervous system, or CNS disease).

Condition Treatment or Intervention Phase
Herpes Simplex
 Drug: Acyclovir Oral Suspension
 Drug: Zovirax Oral Acyclovir (ACV) Suspension
Phase III

MedlinePlus related topics:  Herpes Simplex

Study Type: Interventional
Study Design: Treatment, Randomized, Placebo Control, Parallel Assignment

Official Title: A Placebo-controlled Phase III Evaluation of Suppressive Therapy with Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Involving the Central Nervous System (CASG 103)

Further Study Details: 

Expected Total Enrollment:  66

Study start: August 1997

Infants diagnosed with HSV disease involving the central nervous system (CNS) are routinely treated with intravenous (IV) acyclovir for 21 days. Infants enrolled in this study will have a spinal tap (a procedure which removes fluid from the spinal column), performed before the end of the IV treatment, to test for HSV improvement. If there is improvement (no evidence of HSV), patients are selected to receive oral acyclovir therapy or placebo for 6 months. If there is evidence of HSV, patients will qualify for a Pilot Sub-study and receive additional IV acyclovir.

Eligibility

Ages Eligible for Study:  up to  24 Months,  Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA:

  • 28 days of age or less at the time of initial diagnosis of CNS disease.
  • Weighed at least 800 grams at birth.
  • Has documented CNS disease caused by HSV.
  • Has a negative CSF PCR test within 48 hours prior to the completion of the intravenous acyclovir therapy.

EXCLUSION CRITERIA:

  • Has had bleeding in the brain prior to the study entry.
  • Has poorly functioning kidneys (creatinine greater than 1.5 mg/dL) at time of study enrollment.
  • Was born to a woman known to be HIV positive.
  • Is being breast-fed and the mother is taking acyclovir, valacyclovir, or famciclovir for more than 120 hours (more than 5 days).
  • Infant has HSV infection limited to the skin, eyes, or mouth.
  • He or she may qualify for another protocol (DMID 97-006) if the CNS is not involved.

Location and Contact Information

Penny Jester      877-975-7280    PJester@peds.uab.edu

Alabama
      University of Alabama at Birmingham, Birmingham,  Alabama,  35294,  United States; Recruiting

Arkansas
      University of Arkansas, Little Rock,  Arkansas,  72201,  United States; Recruiting

California
      Cedars-Sinai Medical Center - Los Angeles, Los Angeles,  California,  90048,  United States; Recruiting

      Stanford University, Stanford,  California,  94305,  United States; Recruiting

      Children's Hospital & Health Center - San Diego, San Diego,  California,  92123,  United States; Recruiting

Connecticut
      Connecticut Children's Medical Ctr, Hartford,  Connecticut,  06119,  United States; Recruiting

Florida
      University of Florida HSC - Jacksonville, Jacksonville,  Florida,  32209,  United States; Recruiting

Illinois
      University of Chicago, Chicago,  Illinois,  60637,  United States; Recruiting

Kentucky
      University of Louisville, Louisville,  Kentucky,  40202-3830,  United States; Recruiting

Louisiana
      Tulane University Medical Center, New Orleans,  Louisiana,  70112,  United States; Recruiting

Maine
      Maine Medical Center, Portland,  Maine,  04101,  United States; Recruiting

Maryland
      Johns Hopkins University - Baltimore MD (DIR/IM), Baltimore,  Maryland,  21205,  United States; Recruiting

Michigan
      Children's Hospital of Michigan, Detroit,  Michigan,  48201,  United States; Recruiting

Mississippi
      University of Mississippi, Jackson,  Mississippi,  39216,  United States; Recruiting

Missouri
      Washington University, St. Louis,  Missouri,  63110,  United States; Recruiting

New York
      Mount Sinai Medical Center, New York,  New York,  10029,  United States; Recruiting

      Mount Sinai Medical Center, New York,  New York,  10029,  United States; Recruiting

      SUNY Upstate Medical University, Syracuse,  New York,  13210,  United States; Recruiting

North Carolina
      Carolinas Medical Center, Charlotte,  North Carolina,  28204,  United States; Recruiting

Ohio
      MetroHealth Medical Center of Cleveland, Cleveland,  Ohio,  44109,  United States; Recruiting

      Children's Hospital Res Foundation - Columbus, Columbus,  Ohio,  43205,  United States; Recruiting

      Cincinnati Children's Hospital Med Ctr, Cincinnati,  Ohio,  45229,  United States; Recruiting

Oregon
      Oregon Health and Science University, Portland,  Oregon,  97201-3098,  United States; Recruiting

Rhode Island
      Rhode Island Hospital, Providence,  Rhode Island,  02903,  United States; Recruiting

South Carolina
      Medical University of South Carolina, Charleston,  South Carolina,  29425,  United States; Recruiting

Tennessee
      Vanderbilt University Medical Center, Nashville,  Tennessee,  37232,  United States; Recruiting

      University of Tennessee, Knoxville,  Tennessee,  37920,  United States; Recruiting

Texas
      University of Texas Health Science Ctr - San Antonio, San Antonio,  Texas,  78229,  United States; Recruiting

      Christus Santa Rosa Health Care, San Antonio,  Texas,  78207,  United States; Recruiting

      Southwest Texas Methodist Hospital, San Antonio,  Texas,  78229,  United States; Recruiting

      Cook - Fort Worth Children's Medical Center, Fort Worth,  Texas,  76104,  United States; Recruiting

      Baylor College of Medicine, Houston,  Texas,  77030,  United States; Recruiting

      University of Texas Southwestern Medical Center, Dallas,  Texas,  75235,  United States; Recruiting

Washington
      Children's Hospital Medical Center of Seattle, Seattle,  Washington,  98105,  United States; Recruiting

Canada, Alberta
      University of Alberta, Edmonton,  Alberta,  T6G2B7,  Canada; Recruiting

Canada, Manitoba
      University of Manitoba - Winnipeg, Winnipeg,  Manitoba,  R3T 2N2,  Canada; Recruiting

More Information

Study ID Numbers:  97-007
Record last reviewed:  December 2004
Last Updated:  December 29, 2004
Record first received:  March 6, 2002
ClinicalTrials.gov Identifier:  NCT00031460
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 8, 2005

Resources



Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Metoclopramide Oral Solution.

November 18, 2008



Page Updated: June 1, 2005
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.